Skip to main content

Endonovo Therapeutics Announces Eight Additional Hospitals Approved Use of SofPulse® at Their Facilities

Written by Customer Service on . Posted in Public Companies.

Los Angeles, CA, April 16, 2020 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB: ENDV) (“Endonovo” or the “Company”) today announced the addition of eight new hospitals Endonovo’s SofPulse® medical device is approved for use. The eight hospitals are located in the following geographic areas: 7 Hospitals in Nevada and 1 Hospital in North Carolina.
Endonovo’s SofPulse® is an FDA-Cleared non-invasive therapeutic medical device for reduction of postoperative pain and edema. SofPulse® represents a low-cost, drug-free solution proven in studies to reduce the use of opioids following surgical procedures, which can help prevent opioid dependency. The SofPulse® PEMF (Pulsed Electromagnetic Frequency) therapy is non-invasive and non-pharmacologic with no known side effects and no potential for overdose or dependency. SofPulse® has been proven in clinical studies and in current hospital use to reduce pain and edema postoperatively while improving recovery in patients using the SofPulse® device. Additionally, SofPulse® has been studied extensively in soft tissue post-operative pain management. Learn more at www.sofpulse.com.Endonovo CEO Alan Collier states, “Our Endonovo sales and marketing team continues to expand distribution by working with hospital administrators and medical professionals daily. Adding eight additional hospitals to our distribution network demonstrates SofPulse® marketing efforts are consistently striving to bring this innovative postoperative pain and edema reduction device to the public. Making the SofPulse® device available to every patient having a surgical procedure is our nationwide marketing goal to help resolve the opioid crisis gripping America. With the incredible health benefits SofPulse® provides we are excited about the progress and the strong positive market feedback we have been receiving regarding the demand and need for SofPulse® in hospitals nationwide.”About Endonovo TherapeuticsEndonovo Therapeutics, Inc. is a commercial-stage developer of noninvasive wearable Electroceuticals® therapeutic devices. The Company’s current portfolio of commercial and clinical-stage wearable Electroceuticals® therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and central nervous system (CNS) disorders, including traumatic brain injury (TBI), acute concussions, post-concussion syndrome and multiple sclerosis. The Company’s noninvasive Electroceutical® therapeutic device, SofPulse®, which uses pulsed short-wave radiofrequency at 27.12 MHz, has been FDA-cleared and CE marked for the palliative treatment of soft tissue injuries and post-operative pain and edema and has CMS national coverage for the treatment of chronic wounds. The Company’s current portfolio of preclinical-stage Electroceuticals® therapeutic devices addresses chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The Company’s noninvasive, wearable Electroceuticals® therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur. www.endonovo.com.Safe Harbor StatementThis press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as “anticipate,” “believe,” “plan,” “estimate,” “expect,” “intend,” and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company’s reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company’s estimates as of the date of the press release, and subsequent events and developments may cause the Company’s estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company’s estimates of its future financial performance as of any date subsequent to the date of this press release.Investor Relations Contact:Endonovo Therapeutics, Inc.
Mr. Andrew Barwicki
516-662-9461
Andrew@barwicki.com
www.endonovo.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.